Expert Interview
Discussing the recent phase 3 VALOR clinical trial data on Pfizer's lyme disease vaccine candidate PF-07307405 (LB6V).
Ticker(s): PFE, VALN, MRNAInstitution: Johns Hopkins
- Infectious disease specialist and Director of the Johns Hopkins Lyme Disease Research Center, where he leads one of the most prominent clinical and research programs focused on Lyme disease and tick-borne illnesses.
- Manages ~300 patients per year for lyme disease.
- Internationally recognized authority on post-treatment Lyme disease (PTLD), a condition he helped define, with research focused on disease pathophysiology, long-term outcomes, and improved diagnostic testing.
Are You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
